Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Caris Life Sciences, DermTech, Sonora Quest Laboratories, CellVax, Mainz Biomed

NEW YORK – Caris Life Sciences said this week that the University of Iowa Holden Comprehensive Care Center has joined the Caris Precision Oncology Alliance, a network of cancer centers that collaborate to advance precision oncology and biomarker-driven research. The alliance currently includes 74 cancer centers and academic institutions. 

DermTech and Sonora Quest Laboratories said this week that they have signed an agreement making Sonora Quest the exclusive laboratory in Arizona offering the DermTech Melanoma Test. According to the companies, the agreement will expand Arizona patients’ access to the test, which uses DermTech’s Smart Sticker technology to collect skin cells to be tested for melanoma-associated genomic markers. 

CellVax said this week that it has selected Theragent as a contract development and manufacturing organization (CDMO) to manufacture and test its investigational autologous cancer vaccine FK-PC101. CellVax is about to begin evaluating the treatment in Phase II trials for high-risk prostate cancer patients. Under the terms of the agreement, Theragent will begin providing manufacturing services for CellVax's early and pivotal trials by the end of this year.  

Mainz Biomed said this week that it has initiated eAArly DETECT, a US extension of its European feasibility study, ColoFuture, to evaluate the integration of five novel mRNA biomarkers into its ColoAlert colorectal cancer detection test. The company licensed the biomarkers earlier this year from the Université de Sherbrooke in Quebec, Canada. Both ColoFuture and eAArly DETECT are multi-center studies assessing the potential of these biomarkers to identify advanced adenomas, a type of precancerous polyp associated with CRC. Mainz Biomed plans to complete enrollment for eAArly DETECT in Q1 of 2023 and to report topline results in the first half of the year. Based on the outcome, it may include any of the biomarkers in its US pivotal study, scheduled to start in Q4 of 2022. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.